Advertisement
Advertisement

Read Now: HIV 2014 Year in Review >>

New Danish Results Spark Interest for Future HIV Cure Research

May 23, 2013

 < Prev  |  1  |  2 

Caution Needed

The results from the Danish reanalysis are modest yet promising. However, they need to be interpreted cautiously, at least for the following reasons:

  • Reanalyzing data from a study designed for a different purpose can, at best, yield interesting results. However, such reanalysis cannot produce definitive results. The findings from the Danish study can be used to design a clinical trial to assess the impact of CpG 7909 on changes in the proportion of HIV-infected cells, perhaps with more participants and over a longer period.
  • The reanalysis had additional gaps: The study was not formally designed to assess the impact on the immune system's ability to detect and destroy HIV-infected cells. Therefore, the scientists are not certain how repeated exposure to CpG 7909 apparently reduced the burden of HIV-infected cells.

What is clear is that no one has yet been cured of HIV by repeated exposure to CpG 7909 over a period of 10 months. Also, such a cure -- with this or any other therapy -- is not imminent. Rather, much more study is required of this exciting compound, perhaps in combination with other experimental drugs in HIV-positive people who are taking ART.


Advertisement

Problems With Access to CpG 7909

CpG 7909 was developed by the Coley Pharmaceutical Group, which was then acquired by the pharmaceutical company Pfizer in 2011, along with all of the rights for commercially testing and using CpG 7909 in people. Pfizer is developing a new CpG molecule that recently entered clinical trials, but they have not been providing this to outside groups for testing. CpG 7909 is in cancer vaccines being developed by GlaxoSmithKline as well as in several other cancer vaccines being developed by university-based scientists. Although clinical trials with CpG 7909 are ongoing in HIV-negative people, Pfizer has not continued Coley's policy of providing the compound to academic researchers for their research. Until this situation changes, it is not likely that CpG 7909 will be tested in clinical trials in HIV-positive people.


Not Giving Up

Although the Danish scientists cannot currently access CpGs for clinical trials in people, they are not giving up on cure research. They have at least another approach to a potential cure for HIV. In collaboration with other scientists in Australia, Sweden and the United States, they are testing a drug that will hopefully help to drive HIV out of hiding. This approach has the potential to reduce the burden of HIV-infected cells in the body and make future attempts at a cure perhaps easier. The drug being tested is an experimental cancer therapy called panobinostat, made by the pharmaceutical company Novartis. Panobinostat belongs to a class of drugs called HDAC inhibitors. Interim results from their study of panobinostat will be released later this year. To find out more about HDAC inhibitors and their potential and challenges for curing HIV, see TreatmentUpdate 196.


Cure Research in Context

The journey toward a cure will not be easy and many challenges lie ahead. Some of the challenges are known, others may only become known as experiments proceed. As with any great scientific endeavour, there will be setbacks. The initial wave of cure research experiments over the next five to 10 years should be viewed as exploratory and their results highly preliminary. This research will seek to answer important scientific questions that can then be used to build a foundation toward a cure. In the meantime, research funding agencies need to show patience and sustained funding as hardworking scientists struggle against the many challenges that lie in their path as they search for avenues to explore in the quest for an HIV cure.


Acknowledgement

We thank Ole Søgaard, M.D., and colleagues at Aarhus University, Denmark, and Arthur Krieg, M.D., RaNA Therapeutics, Cambridge, Massachusetts, for their helpful comments, research assistance and expert review.


References

  1. Coley RB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clinical Orthopaedics and Related Research. 1991 Jan;(262):3-11.
  2. Starnes CO. Coley's toxins in perspective. Nature. 1992 May 7;357(6373):11-2.
  3. Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature. 1995 Apr 6;374(6522):546-9.
  4. Tokunaga T, Yamamoto T, Yamamoto S. How BCG led to the discovery of immunostimulatory DNA. Japanese Journal of Infectious Diseases. 1999 Feb;52(1):1-11.
  5. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annual Review of Immunology. 2002;20:197-216.
  6. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annual Review of Immunology. 2002;20:709-60.
  7. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annual Review of Immunology. 2003;21:335-76.
  8. Krieg AM. CpG motifs: the active ingredient in bacterial extracts? Nature Medicine. 2003 Jul;9(7):831-5.
  9. Hirsch I, Caux C, Hasan U, et al. Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends in Immunology. 2010 Oct;31(10):391-7.
  10. Cooper CL, Davis HL, Angel JB, et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS. 2005 Sep 23;19(14):1473-9.
  11. Søgaard OS, Lohse N, Harboe ZB, et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clinical Infectious Diseases. 2010 Jul 1;51(1):42-50.
  12. Winckelmann AA, Munk-Petersen LV, Rasmussen TA, et al. Administration of a Toll-Like Receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients. PLoS One. 2013 Apr 26;8(4):e62074.
  13. Shan L, Siliciano RF. From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication. Bioessays. 2013 Apr 24.
  14. Aarhus University Hospital. Correction to HIV story. Press release. 3 May 2013.
  15. Aarhus University Hospital. Danish scientists get one step closer to a cure. Press release. 1 May 2013.
  16. Krieg AM. CpG still rocks! Update on an accidental drug. Nucleic Acid Therapeutics. 2012 Apr;22(2):77-89.
  17. Rasmussen TA, Tolstrup M, Winckelmann A, et al. Eliminating the latent HIV reservoir by reactivation strategies: Advancing to clinical trials. Human Vaccines & Immunotherapeutics. 2013 Apr 1;9(4).
  18. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012 Jul 25;487(7408):482-5.
  19. Deeks SG. HIV: Shock and kill. Nature. 2012 Jul 25;487(7408):439-40.
  20. Cillo A, Sobolewski M, Coffin J, et al. Only a small fraction of HIV-1 proviruses in resting CD4+ T cells can be induced to produce virions ex vivo with anti-CD3/CD28 or vorinostat. In: Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, U.S. Abstract 371.
  21. Kent SJ, Reece JC, Petravic J, et al. The search for an HIV cure: tackling latent infection. Lancet Infectious Diseases. 2013; in press.
  22. Katlama C, Deeks SG, Autran B, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet. 2013; in press.
  23. Yukl SA, Boritz E, Busch M, et al. Challenges in detecting HIV persistence during potentially curative interventions: A study of the Berlin patient. PloS Pathogens. 2013 May;9(5):e1003347.
  24. Buitendijk M, Eszterhas SK, Howell AL. A Toll-Like Receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Research and Human Retroviruses. 2013 Jun;29(6):907-18
 < Prev  |  1  |  2 



This article was provided by Canadian AIDS Treatment Information Exchange. It is a part of the publication CATIE News. Visit CATIE's Web site to find out more about their activities, publications and services.
 

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Advertisement